The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Outcomes of patients with AML treated with intensive chemotherapy during 1997–2016: A HARMONY Alliance analysis
|
A retrospective analysis assessed the outcomes of patients with AML treated with intensive chemotherapy over four consecutive 5-year calendar periods, 1997–2001 (n = 1,127), 2002–2006 (n = 1,294), 2007–2011 (n = 1,821), and 2012–2016 (n = 1,117), using the HARMONY Alliance database.1 Results from this analysis were published in Haematologica by Sobas et al.1 |
| Key learnings |
| Median OS improved from 15.5 months to 37.8 months over the four calendar periods (p < 0.0001), likely due to a reduction in the early death rate within 60 days of diagnosis from 13.0% to 4.7% (p < 0.0001). |
| Improved OS over time was observed across all patient age groups, genetic risk groups, and in patients treated both with or without allo-HSCT consolidation. |
| Allo-HSCT was associated with a survival advantage in patients aged ≥60 years (p < 0.0001), emphasizing its role as a critical consolidative therapy, even for older populations. |
| Results from this analysis highlighted the improved outcomes in intensively treated patients with AML during 1997–2016, likely due to better therapy management and supportive care, increased referrals for allo-HSCT, and safer application of allo-HSCT in older patients. |
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation, AML, acute myeloid leukemia; OS, overall survival.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?
